NewsRoom Articles - BioMedWire (BMW)

FridayDec 06, 2024 10:00 am

Cases of Parvovirus B19 Spike in the US

Parvovirus B19, often referred to as the B19 virus, is a seasonal respiratory viral illness that is transmitted through respiratory secretions from an infected individual’s sneezes or coughs, their blood or blood products, or through vertical transmission from a pregnant woman to her baby. Common symptoms include joint pain in adults and slapped cheek rash in kids. In persons with weakened immune systems and blood disorders, infection can lead to a low blood count. The disease may also heighten the risk of miscarriage early in pregnancy. Earlier in August, the CDC issued an advisory on the increase in cases of…

FridayDec 06, 2024 8:45 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Emerging therapies, advanced diagnostic tools and groundbreaking research are reshaping the fight against cancer. Calidi Biotherapeutics uses stem cells and cell-enveloping technologies to deliver virotherapy payloads that attack cancers and leave healthy cells untouched. RTNova is designed to address the limitations of traditional virotherapy by offering enhanced targeting, systemic delivery and immune system modulation. Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing the global cancer burden, innovation remains critical to achieving further breakthroughs. Emerging therapies, advanced diagnostic…

ThursdayDec 05, 2024 10:00 am

New Computational Model Explains Behavioral and Neural Differences in ASD

Autism spectrum disorder is a developmental and neurological disorder that affects how an individual communicates with others, interacts with them and behaves, as well as learns. Researchers have developed a new computational model to explain the behavioral and neural differences in autism spectrum disorder. The new model provides new insights into information processing in the brains of persons living with autism, which may in turn broaden the horizons of future studies. The model was designed by Oded Wertheimer and Dr. Yuval Hart from the Department of Psychology at The Hebrew University of Jerusalem. It focuses on the dynamic range, which…

WednesdayDec 04, 2024 9:30 am

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

The company anticipates a 70% increase in membership in the upcoming year, growing the current number of members from 13,000 in June 2024 to 20,000 in 2025. The fourfold increase in membership reflects the growing demand for a change in approach to healthcare that combines innovative personalized strategies with a deep understanding of the served communities. The company has established a strong network of over 12,940 providers, enabling it to offer comprehensive care to its rapidly growing member base, especially in Southern California. Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan, dedicated to reshaping personalized and comprehensive…

TuesdayDec 03, 2024 2:30 pm

Adageis Is ‘One to Watch’

Adageis operates in the rapidly expanding AI healthcare market, projected by Fortune Business Insights to reach $490.96 billion by 2032. The ProActive Care Platform offers seamless integration with existing EMR systems, reducing adoption barriers for healthcare providers. Partnerships with prominent organizations, such as HealthyU Clinics, and its status as an AthenaHealth marketplace partner, demonstrate Adageis’ growing influence in the healthcare sector. The company’s AI-driven predictive analytics enhance patient care and operational efficiency, aligning with the industry’s shift toward value-based care models. Led by a seasoned leadership team with extensive experience in healthcare and technology, Adageis is well-equipped to navigate the evolving healthcare…

TuesdayDec 03, 2024 10:00 am

e-Commerce Sees New Record as Thanksgiving Shoppers Go All Out on Spending

2024 saw Thanksgiving sales increase, with mobile and e-commerce purchases hitting new highs. An analysis conducted by Adobe Analytics determined that by the end of November 28th, online consumers had spent $6.1 billion during Thanksgiving. This figure represents an 8.8% increase from 2023’s Thanksgiving sales. Adobe Digital Insights’ lead analyst Vivek Pandya stated that Cyber Week had started on a strong high, with huge discounts driving impulse shopping in categories like apparel and electronics. Cyber Week refers to the 5-day period which includes Thanksgiving, Black Friday and Cyber Monday. This year, Cyber Monday was on December 2nd. Salesforce, an e-commerce…

TuesdayDec 03, 2024 8:00 am

Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast

The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST. Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session. The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a…

MondayDec 02, 2024 10:00 am

AI Model Promises New Way to Detect Brain Malignancies

Central nervous system and brain cancers accounted for 248,500 deaths globally in 2022. In America, roughly 90,000 brain tumors are diagnosed annually, with data from the American Cancer Society showing that over 25,000 of these tumors are cancerous. It is projected that there’ll be an estimated 25,400 new cases of central nervous system and brain cancers in 2024. Estimates also show that roughly one million individuals in the U.S. live with a primary brain tumor, with about 28% of all brain tumors being malignant. Glioblastoma, a fatal form of brain cancer, accounts for 50% of all malignant brain tumors in…

TuesdayNov 26, 2024 10:00 am

MS Drug Could Counter Poor Working Memory

A new study has determined that a medication normally prescribed for multiple sclerosis can help persons with poor working memory. Working memory is an important component of cognitive function. Sadly, it is often impaired in patients with conditions like schizophrenia. The study was led by University of Basel’s Professors Dominique de Quervain and Andreas Papassotiropoulos. For their randomized and double-blind study, the researchers tested the efficacy of fampridine on the working memory of forty-three healthy adults. Fampridine, the medication in question, is normally used to enhance walking ability for patients with multiple sclerosis. Patients with this chronic illness often experience…

MondayNov 25, 2024 8:45 am

Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression

The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, targeting cancer drug resistance and immune suppression. Kairos Pharma’s lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646, in combination with Apalutamide) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110, in combination with Osimertinib). The company is working with PreCheck Health Services to develop companion biomarkers for ENV-105, with the aim of…